Who is sponsoring NCT03181685?

NCT03181685 is sponsored by Andros Day Surgery Clinic.

What condition does NCT03181685 study?

NCT03181685 studies Infertility, In Vitro Fertilization.

What drugs are being tested in NCT03181685?

Interventions: Progesterone 25 MG subcutaneous, Micronized progesterone 200 MG, recombinant FSH, Cetrorelix Acetate.

What is the status of NCT03181685?

NCT03181685 is currently TERMINATED.

Last reviewed 2020-01-07 · How we verify

Subcutaneous Versus Vaginal Progesterone as Luteal Support in IVF/ICSI Cycles: Which is the Preference Expressed by the Patients?

NCT03181685 Phase 4 TERMINATED

This randomized, controlled, prospective, crossover, open-label, two-treatments, two-period trial aimed to evaluate the preference expressed by the patient concerning the subcutaneous administration of progesterone versus the vaginal one. The couples, scheduled for performing 2 In Vitro Fertilization (IVF)/Intracytoplasmic Sperm Injection (ICSI) cycles will be randomized to receive, as luteal phase supplementation, Pleyris 25 milligram (mg) (a single subcutaneous administration per day) or Prometrium 200 mg (3 vaginal administrations per day).

Details

Lead sponsor	Andros Day Surgery Clinic
Phase	Phase 4
Status	TERMINATED
Enrolment	60
Start date	2016-12-20
Completion	2019-12

Conditions

Infertility
In Vitro Fertilization

Interventions

Progesterone 25 MG subcutaneous
Micronized progesterone 200 MG
recombinant FSH
Cetrorelix Acetate

Primary outcomes

Surveys for testing the satisfaction — Single administration at the end of each treatment cycle (an average of 28 days)
Patient's level of satisfaction will be measured as score on 5-point likert scale + 2 qualitative response

Countries

Italy